Meyahealth
HomeGeneticsConditionMucolipidosis II alpha/beta
Back to Condition
Mucolipidosis II alpha/beta
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Mucolipidosis II alpha/beta

Also known as I-cell disease, this is a progressively debilitating lysosomal storage disorder that affects skeletal development, growth, and organ function.

Overview

Mucolipidosis II alpha/beta is a rare, progressively debilitating disorder that affects many parts of the body. Most affected individuals do not survive past early childhood. At birth, children are typically small with weak muscle tone (hypotonia) and a weak cry. Growth usually slows significantly after birth and stops during the second year of life.

Symptoms

Key features of the condition include:

  • Developmental delays: Particularly in speech and motor skills like sitting and standing.
  • Skeletal abnormalities: Including an abnormally rounded upper back (kyphosis), rotated feet, dislocated hips, and joint deformities (contractures) that limit mobility.
  • Dysostosis multiplex: Multiple skeletal abnormalities visible on X-rays.
  • Physical features: Umbilical or inguinal hernias, heart valve abnormalities, distinctive facial features, and overgrowth of the gums.
  • Respiratory and ear issues: A narrow airway and stiffened tissues can lead to a hoarse voice and recurrent respiratory infections. Recurrent ear infections may lead to hearing loss.

Causes

Mucolipidosis II alpha/beta is caused by mutations in the GNPTAB gene. This gene provides instructions for an enzyme called GlcNAc-1-phosphotransferase, which is responsible for "tagging" digestive enzymes with a molecule called mannose-6-phosphate (M6P). This tag acts as a signal to transport these enzymes to lysosomes, the cell's recycling centers.

When this enzyme is missing or non-functional, digestive enzymes are not transported to lysosomes and instead end up outside the cell. This causes large molecules to build up inside the lysosomes, characterizing the condition as a lysosomal storage disorder.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell must have mutations. Parents of an affected individual each carry one copy of the mutated gene but typically do not show signs or symptoms of the condition.

Other Names

  • I-cell disease
  • Inclusion cell disease
  • MLII
  • Mucolipidosis II
  • Mucolipidosis type II

Frequently Asked Questions

Key early clues include persistent hypotonia (weak muscle tone), poor feeding and failure to thrive, a weak cry, and a characteristic facial appearance (prominent forehead, wide mouth). Umbilical or inguinal hernias, joint contractures (especially in the hips and knees), and a small, stiff tongue are also common. If these features appear together, a referral to a metabolic or genetic specialist is warranted for further evaluation. How can physical therapy and occupational therapy help improve joint mobility and daily functioning in affected children?::Therapists focus on gentle stretching, range‑of‑motion exercises, and strengthening to slow the progression of contractures. Splinting or orthotic devices can maintain joint alignment. Occupational therapy addresses fine‑motor skills and adaptive strategies for feeding, dressing, and play. Early, consistent intervention can preserve function, reduce pain, and improve quality of life. What surgical options are available for skeletal abnormalities, and when should they be considered?::Surgical interventions are usually reserved for severe deformities that impair function or cause pain. Options include corrective osteotomies for bowed limbs, joint replacement for severely arthritic hips or knees, and airway procedures (e.g., tracheostomy or laryngoplasty) if breathing is compromised. Timing depends on the rate of progression, the child’s overall health, and the potential benefit versus surgical risk. A multidisciplinary team evaluates each case individually. Are there any emerging treatments or clinical trials that target the underlying enzyme deficiency?::Research is exploring gene therapy to restore functional GNPTAB enzyme, as well as substrate‑reduction strategies that limit the buildup of undegraded molecules. Small‑molecule chaperones that enhance residual enzyme activity are also under investigation. Clinical trials are limited but ongoing; families can contact specialized centers or registries to learn about eligibility and participation.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ